Skip to content

Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (Nat-Geno)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06960798
Enrollment
150
Registered
2025-05-07
Start date
2026-05-02
Completion date
2029-06-30
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Native American Men, Genomic Profile

Brief summary

The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.

Detailed description

This study aims to establish a comprehensive database of Native American (NA) patients diagnosed with prostate cancer (PC), focusing on an in-depth characterization of the genomic landscape. Archived tumor tissue collected at screening and peripheral blood samples obtained within the first year of enrollment will serve as the basis for comprehensive molecular analyses. Whole exome sequencing (WES) and whole transcriptome sequencing (RNA-seq) will be performed to characterize and delineate the genomic and transcriptomic landscape of the study cohort. The study will initially enroll participants at the Stephenson Cancer Center, with planned expansion to additional sites across Oklahoma and, subsequently, to other institutions across the United States. Oversight will be maintained by the Tribal Institutional Review Board and an independent Community Advisory Board to ensure cultural appropriateness, transparency, and sustained community engagement throughout the research process. The overarching objective is to generate insights that will inform the development of personalized treatment strategies in the future.

Interventions

Tissue samples will be taken from existing archived collections and sent for further analysis.

OTHERBlood Draw

Blood samples will be collected within the first year of enrollment.

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses. * At least 18 years-of-age at the time of signature of the informed consent form (ICF). * Patients who self-identify as Native American. * Patients with a pathologically proven diagnosis of PC (any stage). * Availability of most recent archived tumor samples.

Exclusion criteria

* Patients not of Native American descent or identity. * Patient does not have archival tissue available.

Design outcomes

Primary

MeasureTime frameDescription
Difference in the genomic profiles of Prostate Cancer1-3 yearsComprehensively characterize the genomic profile of prostate cancer in Native American patients compared to Caucasian patients. Genetic testing will be conducted using Caris Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS).

Secondary

MeasureTime frameDescription
Comparison of Genomic Profiles1-3 yearsThe study compares the Native American population with a reference Caucasian cohort to characterize molecular disparities and evaluate their clinical significance.

Countries

United States

Contacts

CONTACTLead Onco Nurse
SCC-IIT-Office@ouhsc.edu405-271-8777
CONTACTAdanma Ayanambakkam, MD
Adanma-Ayanambakkam@ouhsc.edu405-271-4022
PRINCIPAL_INVESTIGATORAdanma Ayanambakkam, MD

University of Oklahoma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026